Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation

Bone Marrow Transplantation volume 37, pages 625–626 (2006)Cite this article

There is a risk of fatal reactivation of hepatitis B virus (HBV) among HBs-Ag positive patients undergoing hematopoietic stem cell transplantation (HSCT).1 However, active antiviral therapy may modify the natural history of HBV infection during immunosuppression and immune recovery following HSCT.

We report a case of an HBs-Ag positive patient who, despite lamivudine prophylaxis, developed a severe HBV reactivation after a reduced intensity conditioning (RIC) HSCT, which was finally controlled by adefovir.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Strasser SI, McDonald GB . Hepatitis viruses and hematopoietic cell transplantation: a guide to patient and donor management. Blood 1999; 93: 1127–1136.

    CAS  Google Scholar 

  2. Perez-Roldàn F, Gonzàles-Carro P, Villafànez-Garcia MC . Adefovir dipivoxil for chemotherapy-induced activation of hepatitis B virus infection. N Engl J Med 2005; 352: 310–311.

    Article  Google Scholar 

  3. Lau GK, He ML, Fong DY, Bartolomeusz A, Au WY, Lie AK et al. Preemptive use of lamivudine reduces hepatitis B exacerbation after allogeneic hematopoietic cell transplantation. Hepatology 2002; 36: 702–709.

    Article  CAS  Google Scholar 

  4. Rossi G . Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003; 44: 759–766.

    Article  CAS  Google Scholar 

  5. Marcellin P, Chang TT, Lim S, Sievert W, Tong M, Aterburn S et al. Long term efficacy and safety of Adefovir dipivoxil (ADV) 10 mg in HBe Ag+ chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time (abstract). Hepatology 2004; 40: 655A (abstract 1135).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hopital Saint Antoine AP HP, Hematologie, 184 rue du Faubourg Saint Antoine, Paris, France

    L Fouillard, L Serfaty & J Gozlan

Authors
  1. L Fouillard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Serfaty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Gozlan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L Fouillard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fouillard, L., Serfaty, L. & Gozlan, J. Adefovir therapy for lamivudine escape and hepatitis B virus reactivation after reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 37, 625–626 (2006). https://doi.org/10.1038/sj.bmt.1705290

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705290

This article is cited by

Search

Advanced search

Quick links